Lerner left Oregon in 1955 to become chief of dermatology at Yale University, and Fitzpatrick eventually became chair of dermatology at Harvard University. Lerner spent the rest of his career at Yale, where he reached the pinnacle of his specialty. He was the first dermatologist elected to the prestigious National Academy of Sciences.
The color of skin was a lifelong fascination for Lerner. He believed that the twenty-first century would bring cures for vitiligo, melanoma, and many other pigmentary disorders and that someday people would be able to change the color of their skin at will.
Fitzpatrick and Lerner were the first to use psoralen (a plant derivative that increases skin sensitivity to light) together with ultraviolet light to treat psoriasis, vitiligo, dermatitis, and other skin disorders. They were also the first to treat eczema with topical steroids (fluorinated compounds), a therapy that is still widely used.
During his years in Oregon, Lerner began the isolation of melanocyte-stimulating hormone (MSH), a hormone that he and Fitzpatrick suspected could darken skin color. Those studies set the stage for Lerner's isolation of MSH at Yale in 1956. He injected the MSH first into frog skin before trying it in humans in the early 1960s.
The January 21, 1969, issue of the journal Nature described Lerner and Dr. Joseph McGuire's experiment to darken the skin of four African Americans using MSH. Journalist Grace Halsell, the author of Soul Sister (1969), was among several whites who darkened their skin to examine social issues of the 1960s.
In 1957, Lerner and his colleagues isolated and determined the molecular structure of melatonin; they published their results in 1958. The discovery of the hormone set off a cascade of research, including groundbreaking studies by Oregon Health and Science University researchers in the 1980s that elucidated melatonin's role in biologic rhythms. 
